or were removed from the list because of recovery or other reasons were censored. The primary end point for posttransplant outcomes was death or graft loss (retransplantation). For analysis of wait-list outcomes, children were followed from the time of listing until death, HT, removal from the list, or the day of last observation on March 31, 2011. For analysis of posttransplant outcomes, children who received an HT were followed until death, retransplant, or the day of last observation.
Baseline variables were defined at the time of listing for analysis of wait-list outcomes and at transplant for analysis of posttransplant outcomes. Race/ethnicity was recorded as reported by the transplant center and analyzed as white (non-Hispanic white), black (non-Hispanic Black), Hispanic, or other. Renal function was analyzed as estimated glomerular filtration rate (mL/min per 1.73 m 2 ) and calculated from serum creatinine using the modified Schwartz formula. 12 Normal renal function in children ≥1 year of age was defined as glomerular filtration rate >60, moderate dysfunction as 30 to 60, and severe dysfunction as <30/dialysis support. 13 Because of the lower glomerular filtration rate in normal infants <1 year of age, normal renal function, moderate dysfunction, and severe dysfunction were defined as glomerular filtration rate >40, 20 to 40, and <20/dialysis support, respectively. 13 None of the children analyzed had missing data for the variables age, sex, race/ethnicity, blood type, mechanical support at listing or transplant, medical insurance (Medicaid), UNOS listing status, dialysis and the dates of listing, transplant, death, or removal from the wait-list. Missing values of creatinine (3.3% of children at listing and 3% at transplant) and total serum bilirubin (6.3% of children) were imputed using multivariable linear regression analyses.
Statistical Analysis
Summary data are presented as median (25th, 75th percentile) or number (percent). Baseline characteristics between children with dilated, hypertrophic, and restrictive CMP were compared using the χ 2 test for categorical and the Kruskal-Wallis test for continuous variables. Waitlist outcomes in children with dilated and nondilated CMP were characterized using competing outcomes analysis. 14, 15 A multivariable Cox proportional hazards model for the composite wait-list end point was developed using a forward selection procedure, retaining variables significant at the 0.10 level based on a likelihood ratio test; all Table 1 variables were considered. Posttransplant survival (freedom from death or retransplantation) was characterized using Kaplan-Meier survival analysis and compared using the log-rank test. A Cox regression model was used to compare posttransplant outcomes between HT recipients with dilated and nondilated CMP adjusted for baseline risk factors. Assumptions for Cox models were evaluated for both wait-list and posttransplant end points. For both models, interaction of CMP phenotype with other risk factors was evaluated to identify CMP subgroups at increased risk.
Data were analyzed using SAS statistical software version 9.3 (SAS Institute Inc, Cary, NC). All statistical tests were 2-sided, and a P value <0.05 was used to define statistical significance. The authors had full access to the data and take responsibility for its integrity. All authors have read and agree to the manuscript as written.
Results

Study Population
During the study period, 3207 children <18 years of age were listed in the United States for an HT. Of these, 211 children were listed for retransplantation and 17 children for multiorgan transplantation. Of the 2979 children listed for a primary HT, 1436 (48%) children had CMP as their listing diagnosis and formed the study cohort. Of these, 1197 (83%) had dilated CMP and 239 (17%) had nondilated CMP (167 restrictive CMP, 72 hypertrophic CMP). Baseline characteristics of children with dilated CMP and nondilated CMP at the time of HT listing are summarized in Table 1 .
Children with dilated CMP were more likely to be listed with higher urgency as UNOS status 1A 16 candidates (72% of dilated CMP versus 38% of nondilated CMP). They were more likely to be supported with intravenous inotropes (51% of dilated CMP versus 26% of nondilated CMP), a ventilator (27% versus 13%), ventricular assist device (11% versus 1%), and any mechanical support (29% versus 7%) compared with children with nondilated CMP at listing (P<0.001 for all). The median pulmonary artery pressure and pulmonary capillary wedge pressure were similar among children with dilated and those with nondilated CMP. Among infants <1 year old at listing with CMP (n=350), those with dilated CMP (n=314) and nondilated CMP (n=36) were equally likely to be listed as status 1A (80% versus 78%) and supported on a ventilator at the time of listing (48% versus 44%). Although 20% of infants with dilated CMP were on mechanical support (15% on extracorporeal membrane oxygenation, 1% on biventricular assist device, 4% on left ventricular assist device) at listing compared with 11% of infants with nondilated CMP (all on extracorporeal membrane oxygenation), this difference was not statistically significant (P=0.24).
Wait-List Outcomes
Overall, 152 (11%) children with CMP reached the composite wait-list end point (109 died on the wait-list, 43 became too sick to transplant). Figure 1 illustrates competing outcomes for children with dilated CMP ( Figure 1A ), those with nondilated CMP (Figure 1B) , and the cumulative percentage of children in the 2 groups who died on the wait-list or became too sick to transplant ( Figure 1C) . Overall, 11% of children with dilated CMP and 8% of children with nondilated CMP died on the wait-list or became too sick to transplant. The incidence rate of dying on the wait-list or becoming too sick to transplant was 30.2/100 patient-years in children with dilated CMP (95% CI, 25.3-35.8/100 patient-years) and 16.6/100 patient-years in children with nondilated CMP (95% CI, 10.0-25.9/100 patient-years).
Children with nondilated CMP had a lower unadjusted risk of dying on the wait-list or becoming too sick to transplant (hazard ratio [HR], 0.6; 95% CI, 0.4-0.9; P=0.02) compared with children with dilated CMP. Other univariable factors associated with higher risk of reaching the composite waitlist end point were younger age, listing status 1A, ventilator support, mechanical support, and renal dysfunction. Race/ ethnicity and pulmonary artery pressure were not associated wait-list mortality. Among children listed as status 2 (n=303), 3 (2.7%) of 110 children with nondilated CMP and 12 (6.2%) of 193 children with dilated CMP reached the composite waitlist end point (HR, 0.4; 95% CI, 0.1-1.4; P=0. 14) .
In multivariable analysis, independent risk factors for waitlist mortality (or becoming too sick to transplant) included age <1 year, ventilator support, mechanical support, and renal dysfunction ( Table 2 ). In addition, a significant interaction between the CMP phenotype and ventilator support was identified. Children with nondilated CMP were at higher risk of wait-list mortality versus children with dilated CMP only if they were supported on a ventilator at listing (HR, 2.3; CI, 1.2-4.5). The risk was similar in those who were not on ventilator support (HR, 0.6; CI, 0.3-1.1). Importantly, the interaction of CMP phenotype with age at listing was not significant, and there was no difference in wait-list mortality between infants (or older age groups) with dilated and nondilated CMP. In subgroup analysis, the risk of death on the wait-list (or becoming too sick to transplant) in infants with nondilated CMP was Figure 2 illustrates the cumulative transplant rate in children with dilated and nondilated CMP. Overall, 910 children with dilated CMP and 184 children with nondilated CMP received an HT. The median waiting time was 32 days (interquartile range, 11-76 days) in children with dilated CMP and 54 days (interquartile range, 18-118 days) in children with nondilated CMP (P<0.001). Among 303 study children listed as status 2 candidates, 226 (75%) received an HT. Of these, 71% of those with dilated CMP and 54% of those with nondilated CMP received HT after listing upgrade to a higher urgency status (1A or 1B). Of the children who received an HT, 23% of those with dilated CMP and 5% of those with nondilated CMP were supported on a ventricular assist device at the time of HT (see Table 3 for baseline variables at HT).
Posttransplant Outcomes
The median posttransplant follow-up period was 2 years (11 months, 4 years), during which 141 children died or lost their graft (123 deaths, 18 retransplants). Figure 3 illustrates posttransplant Kaplan-Meier survival in children with dilated CMP and nondilated CMP. There was a trend toward better survival in children with dilated CMP compared with children with nondilated CMP both at 30 days (98.1% versus 95.5%) and at 1 year (94.3% versus 88.5%); however, the difference did not reach statistical significance (P=0.17). *Because patients on ECMO are also supported on a ventilator, the risk in ECMO patients is higher compared with risk in BIVAD patients not on a ventilator 
Discussion
This study has 4 major findings. First, children with dilated CMP are, on average, sicker at the time of listing and are listed with higher urgency compared with children with nondilated CMP. Second, several risk factors associated with wait-list mortality, such as age <1 year, level of hemodynamic support, and renal function, are also associated with posttransplant mortality. As a result, CMP children with higher risk of waitlist mortality are also at higher risk of posttransplant mortality on receiving an HT. Third, in adjusted analysis, the risk of death on the wait-list (or becoming too sick to transplant) is similar in children with dilated and nondilated CMP who are not supported on a ventilator at listing. However, among children supported on a ventilator, this risk is 2.3-fold in those with nondilated CMP. Finally, despite a higher risk of posttransplant graft loss in children with nondilated CMP, their posttransplant 1-year survival of 89% approaches the current 1-year posttransplant survival in children. 1, 17 These findings are important in informing clinical decisions during HT evaluation and for parental counseling in these children.
An important previous report in a cohort similar to ours is from the Pediatric Heart Transplant Study (PHTS). The authors reported outcomes in 1320 children with CMP (83% with dilated CMP and 17% with nondilated CMP) listed for HT during 1993-2006. 6, [8] [9] [10] The overall wait-list mortality was higher at 17% reflecting the earlier era (versus 11% for the composite wait-list end point in the current analysis), and posttransplant 1-year survival was 91%. Children with nondilated CMP (particularly those <1 year) and black children were reported to be at higher risk of wait-list mortality. The present study cohort had important differences in baseline characteristics and outcomes from children in the PHTS analyses. First, the use of VAD in the present cohort far exceeds that in the previous analyses as the EXCOR Berlin Heart has gradually become the preferred mechanical circulatory support in children who fail conventional medical therapy. 18 The outcomes and risk factors, therefore, pertain more closely to contemporary support options in the United States. We found that the risk of death on the wait-list and in the posttransplant period associated with mechanical support is hierarchical, being highest in children with extracorporeal membrane oxygenation and less so in children on biventricular assist device and left ventricular assist device. Second, the degree of renal dysfunction is an important risk factor for wait-list and posttransplant mortality. This finding was not reported in the PHTS report but is consistent with our previous work in other cohorts. 7, [19] [20] [21] Third, although black children remain at higher risk of posttransplant mortality, 1 we did not find any association of race/ethnicity with wait-list mortality. This finding is consistent with a recent report that showed that racial gaps, previously present in children awaiting HT in the United States, are absent in the current era. 2 Finally, wait-list and posttransplant outcomes in children with dilated and nondilated CMP seem to have improved compared with the PHTS analyses. 6, [8] [9] [10] The interaction of CMP phenotype with ventilator support as a determinant of wait-list mortality is an important new finding and may be explained by examining current management options in children supported on a ventilator at listing. Although assisted ventilation can be lifesaving in children with severe heart failure, ventilator dependence is an accepted indication for VAD implantation. This is so because VAD implantation reduces the risk of multiorgan failure in these children and allows patient rehabilitation while awaiting HT. 18 This option is readily available to infants and children with dilated CMP with the availability of Berlin EXCOR heart. 18 In contrast, a nondilated left ventricle is a technical challenge for VAD implantation because of space constraints in the left ventricle. The inflow cannula in these children is often placed in the left atrium, a strategy which increases the risks of VAD support 18, 22 and limits available options in children with nondilated CMP who are ventilator dependent.
The higher risk of posttransplant mortality in children with nondilated CMP is not well explained by our data. Because children with nondilated forms of CMP often have a physiology that does not benefit from intravenous inotropes, they may be sicker at the time of HT than their urgency at listing and transplant indicate. It may also be that some children with unique features, such as systemic malformations, syndromes, or inborn errors of metabolism associated with nondilated CMP, were listed and contributed to their increased risk; this speculation is not supported by data, however.
The findings of this study have important implications. First, a close examination of the risk models for wait-list and posttransplant mortality (Tables 2 and 4) suggests that the risk associated with nondilated CMP phenotype is small compared with the aggregate risk associated with factors, such as age, patient support, and end-organ function. Furthermore, overall wait-list and posttransplant outcomes in children with nondilated CMP approach those in children with dilated CMP. Therefore, a diagnosis of nondilated CMP in itself should not deter listing in a child, and the decision should be individualized based on presenting features, comorbidities, and risk assessment. Second, in an allocation system that prioritizes children on the wait-list based on transplant urgency (as the intent of the current system is), 16 the differences in outcomes between the CMP groups do not appear large enough to merit allocation prioritization by CMP phenotype at any age. Third, the similarity in risk factors for wait-list and posttransplant mortality suggests that the sickest children with CMP on the wait-list are also at a higher risk of posttransplant mortality. Models such as those presented may allow estimation of these risks using values of variables at the time of listing. This approach may allow estimation of transplant benefit at the time of listing similar to the current practice in lung transplant candidates in the United States. 23 Considering transplant benefit in addition to transplant urgency in allocation policy may help avoid futile transplants and lower overall mortality in children listed for HT.
This study has several limitations. First, being a retrospective analysis of a national database, the submitted data may lack the rigor and quality control expected of data from a prospective, controlled study. However, because these data are used by UNOS for real-time organ allocation and for periodic auditing of transplant centers, certain safeguards to data quality are to be expected. Second, because of their small sample size and low event frequency, we chose to analyze outcomes in children with nondilated CMP as a single group. This approach is similar to that used in a previous multicenter analysis 6 and allows comparison of outcomes in the 2 cohorts. Third, the risks associated with predictors of wait-list mortality are applicable only in the context of the current heart allocation in the United States 16 and may be different in countries with different allocation policies or donor availability. Finally, our analysis is limited to children already listed for HT and does not provide any insight into natural history of children with CMP, selection criteria for HT listing, or outcomes in children not listed.
In conclusion, children with dilated CMP listed for HT are, on average, sicker at the time of listing than children with nondilated CMP. The risk of wait-list mortality is higher in children with nondilated CMP who are supported on a ventilator at listing but not in those who are not supported on a ventilator. Among those who receive HT, the risk of death or graft loss is modestly higher in children with nondilated CMP. However, their short-term transplant outcomes are good, and their 1-year survival of 89% approaches the current overall posttransplant survival in children. 
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